Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Inmune Bio Inc (INMB)

Inmune Bio Inc (INMB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Inmune Bio Inc 225 NE Mizner Blvd. Suite 640 Boca Raton FL 33432 USA

P: 858-964-3720

Description:

INmune Bio Inc. is a clinical-stage biotechnology company. It engages in developing therapies targeting the innate immune system in cancer. The company's product platform consists of INKmune and INB03. INKmune is a natural killer cell therapeutic which primes the patient's NK cells to attack developing disease. INB03 inhibits myeloid derived suppressor cells which often cause resistance to immunotherapy, such as anti-PD1 checkpoint inhibitors. INmune Bio Inc. is based in La Jolla, United States.

Key Statistics

Overview:

Market Capitalization, $K 111,804
Enterprise Value, $K 51,454
Shares Outstanding, K 17,946
Annual Sales, $ 180 K
Annual Net Income, $ -30,340 K
Last Quarter Sales, $ 20 K
Last Quarter Net Income, $ -6,840 K
60-Month Beta 1.93
% of Insider Shareholders 34.20%
% of Institutional Shareholders 11.21%
Float, K 11,808
% Float 65.80%
Short Volume Ratio 0.20

Growth:

1-Year Return -67.59%
3-Year Return 22.16%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.38 on 08/03/22
Next Earnings Date 11/02/22
Earnings Per Share ttm -1.87
EPS Growth vs. Prev Qtr 2.56%
EPS Growth vs. Prev Year 13.64%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

INMB Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -41.87%
Return-on-Assets % -33.73%
Profit Margin % -16,855.56
Net Margin % N/A
Debt/Equity 0.19
Price/Sales 659.34
Price/Cash Flow N/A
Price/Book 1.71
Book Value/Share 3.90
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar